FDA PMTA Safe Harbor Faces Federal Court Challenge

On July 14, 2026, a coalition of seven national health organizations, a pediatrician and a parent filed suit in the U.S. District Court for the District of Maryland asking a federal judge to throw out the FDA's May 2026 enforcement guidance for electronic nicotine delivery systems and oral nicotine pouches. For most of the U.S. vapor market, that guidance is the reason product is still moving.

This is not a flavor fight or a state registry skirmish. The case targets the single policy document that currently separates a brand with a filed premarket tobacco product application from a brand that never filed at all. If the plaintiffs win, that distinction disappears, and the compliance posture of every wholesale buyer in the category changes with it.

What the May 2026 Guidance Actually Grants

The guidance, announced in the Federal Register on May 12, 2026 and effective immediately, does not legalize anything. It restates plainly that every new tobacco product marketed without a marketing granted order remains illegal. What it does is tell industry where the agency intends to spend its enforcement resources.

FDA said it generally will not prioritize enforcement against a product when a PMTA has been accepted and filed, or when an accepted supplemental PMTA has been pending for more than 180 days. Non-tobacco-flavored products carry an additional condition: the application must contain data the agency considers sufficient to conduct a public health evaluation.

The carve-outs matter as much as the grants. Lower enforcement priority does not extend to products with obvious youth-appealing features, such as cartoon characters or packaging built to resemble toys, phones or gaming devices. FDA also reserved the right to act on products presenting unusual safety concerns, including fire hazards, missing child-resistant packaging and unusually high nicotine content. The agency further committed to publishing a public list of the products covered by the lower priority.

What the Plaintiffs Are Asking the Court to Do

The plaintiffs are the Campaign for Tobacco-Free Kids, the American Academy of Pediatrics, the American Cancer Society Cancer Action Network, the American Heart Association, the American Lung Association, Truth Initiative and Parents Against Vaping, joined by a pediatrician and a parent. They are represented by the legal teams of the Campaign for Tobacco-Free Kids and Democracy Forward.

Their complaint advances three arguments. First, that the guidance exceeds FDA's authority under the Tobacco Control Act by allowing new tobacco products to be marketed indefinitely without the prior authorization the statute requires. Second, that it violates the Administrative Procedure Act because the agency bypassed public notice and comment. Third, that it is arbitrary and capricious, offering no meaningful justification for creating an enforcement safe harbor or for reversing the agency's longstanding position on flavored products. They also ask the court to stop FDA from publishing its promised list, arguing the list would function as a de facto permission slip.

FDA's own rationale, stated in the Federal Register notice, was resource allocation: concentrate enforcement on the products least likely to satisfy the public health standard, encourage stronger applications, and manage an orderly transition toward a regulated market. The question in front of the court is narrow but consequential. Can enforcement discretion lawfully distinguish an applicant waiting in the agency's queue from a seller who never joined it, or must both be treated the same until FDA acts?

Why the Maryland Venue Should Get Your Attention

Several of the same organizations won a 2019 ruling in this same district against an earlier FDA compliance policy that had let e-cigarettes remain on the market without authorization. That decision is what produced the September 9, 2020 PMTA submission deadline that reshaped the entire category. The plaintiffs chose this forum deliberately, and the precedent is the reason.

None of that guarantees the outcome here. It does mean brands and distributors should treat the current safe harbor as provisional rather than settled. Building a twelve-month sales plan on the assumption that the guidance survives judicial review is a bet, not a strategy.

The Practical Exposure Sits With Whoever Holds Inventory

If a court vacates the guidance, the tiering collapses and every unauthorized product returns to the same enforcement footing. The tools available to the agency in that posture are well documented: warning letters, import alerts, seizures, civil money penalty complaints, and DOJ injunction actions against manufacturers. FDA has used all of them, and CTP has been visibly more active on illicit product this year.

Distributors, wholesalers and retailers absorb most of that risk in the form of stranded inventory. It compounds with pressure already building at the state level, including PMTA registry laws in a growing number of states and newer sourcing restrictions such as Indiana's foreign-adversary e-liquid ban, which took effect July 1, 2026.

What to Tighten Now, Regardless of How the Case Goes

The work that protects a brand under either outcome is documentation, and none of it requires waiting for a ruling.

Confirm application status in writing, SKU by SKU. "Submitted" is not the same as "accepted and filed," and the guidance turns entirely on the latter. Get the acceptance letters into a file you can produce on demand.

Verify that the formulation in production matches the formulation in the application. That means the specific flavor house and flavor code, the complete ingredient list, nicotine type and strength, and VG/PG ratio, not an approximation carried forward from an older spec sheet.

Keep batch records that let you reconstruct any lot after the fact: raw material lot numbers, actual weights, compounding date, operator, and finished quantity. If the agency or a state regulator asks what went into a specific bottle, the answer needs to exist on paper.

Review packaging and marketing against the youth-appeal carve-outs before the next print run rather than after a warning letter. The guidance is explicit about what it will not protect.

Plan for the public list. If FDA publishes it, appearing on it will be worth little without the underlying records showing that what is in the bottle matches what is in the application.

Where Manufacturing Fits

Every item on that list depends on the manufacturing side of the relationship. A contract manufacturer that cannot produce a standardized formulation record or a batch document on request is a liability in a market where the enforcement rules can change by court order.

Nova Manufacturing is a U.S.-based e-liquid contract manufacturer built around exactly that requirement: standardized, versioned formulations for every SKU, full batch documentation for every production run, and GMP-quality process controls throughout compounding and filling. Whether you are supporting a pending PMTA, preparing state registry filings, or moving production onshore, we can tell you precisely what went into every bottle we make.

If you want your formulations and production records in shape before the next regulatory turn, get in touch with our team to talk through your SKUs, volumes and documentation needs.